Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept.

Conclusions. There seems to be a linear progression rate of RPE loss in patients treated with ranibizumab as well as in patients with aflibercept. No significant increase of progression rate was found after switch to aflibercept. PMID: 28316836 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/28316836?dopt=Abstract

Source: Journal of Ophthalmology - March 23, 2017 Category: Opthalmology Tags: J Ophthalmol Source Type: research